FDA panel will discuss switch to an annual booster in the fall, akin to flu vaccination strategy
Via HAS-veille
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
|
Some researchers believe nasal vaccines, which aim to induce mucosal immunity, might guard against infection. Thålin has found some intriguing clues in a study that has carefully documented vaccinations and infections in 2000 health care workers in Sweden since April 2020. In September 2022, she and her colleagues reported that people who were infected early in the pandemic, before they were vaccinated, had detectable levels of SARS-CoV-2–specific antibodies of a type named IgA in their noses. The antibodies were not seen in a vaccine-only group. Thålin thinks nasal vaccines would be more effective than current shots at stimulating such antibodies, which might block COVID-19 infections right where they start, in the respiratory tract.
Gommerman is intrigued by the potential for IgA antibodies in the nose and saliva as well. Right now, which level of IgA is an effective shield against infection is still unclear, she says, but “scientists are coming together to figure this out.”